AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02806674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The eradication times of the patients
Description: The patients who have failed more than 2 eradication courses with standardized treatment were the refractory infection of H. pylori group,and patients who succeeded at the first standardized treatment were the successful treatment group
Study NCT02806674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The result of 13C-urea breath test after treatment
Description: The intervention focused on the results from the result of 13C-urea breath test after treatment.The two groups were treatment based on the antibiotic susceptibility testing. Eight weeks after treatment,a 13C-urea breath test was performed on patients.The successful treatment group were patients with negative in 13C-urea breath tests in the first treatment. The refractory infection of H. pylori group were treatment failure patients after the second standardized treatment.
Study NCT03212638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib suspension
Description: Administered orally
Study NCT03212638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib tablet
Description: Administered orally
Study NCT04633148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Non-IMP)
Description: Intravenous infusion for 3 days
Study NCT04633148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine (Non-IMP)
Description: Intravenous infusion for 3 days
Study NCT04633148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UniCAR02-T-pPSMA
Description: Intravenous Infusion for 21 days
Study NCT04633148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UniCAR02-T (IMP)
Description: Intravenous infusion of single dose
Study NCT00005820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitrocamptothecin
Study NCT01286636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computer model
Description: Diagnosis of Sleep apnea and treatment guidance will rely on a computer model prediction.
Study NCT01286636 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polysomnogram
Description: Diagnosis of sleep apnea will rely on polysomnogram
Study NCT01765374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESAOTE MyLab60
Description: US evaluation at different time points
Study NCT01765374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT02950883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Treatment Group 7% Hypertonic Saline
Description: Drug: 7% Hypertonic Saline (HS) 4 mL of HS will be administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI compressor (PARI Vios® Pro in USA, PARI BOY SX in Australia and Europe).~Other Names:~Hyper-Sal™, inhaled saline
Study NCT02950883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Group 0.9% Isotonic Saline
Description: Drug: 0.9% Isotonic Saline (IS) 4 mL of IS will be administered via inhalation twice daily for 48 weeks The delivery system is the same as that for the test product.~Other Names: Normal saline
Study NCT00828126 — intervention group
Intervention type: PROCEDURE
Intervention: PET-CT Scan
Description: Positron emission tomography-computed tomography (PET-CT) scan performed within 30 days of contrast-enhanced CT.
Study NCT01828671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucose Solution 296 mls
Description: Should the participant be eligible to participate, they will be scheduled for two separate study visits to assess the glycemic response of the oral glucose solution.
Study NCT02737189 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Medical Treatment
Description: Best Medical Treatment and maximum supportive care, not including mechanical thrombectomy, no intra arterial treatment
Study NCT02737189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Treatment
Description: Best Medical Treatment and maximum supportive care, not including mechanical thrombectomy, no intra arterial treatment
Study NCT01630252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PGL5001
Description: PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
Study NCT01630252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PGL5001 matching placebo (twice a day) for 8 weeks + one unique DMPA 150 mg injection
Study NCT01630252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PGL5001
Description: PGL5001 320mg/day (160 mg twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
Study NCT01630252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PGL5001 matching placebo (twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
Study NCT01630252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGL5001
Description: PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
Study NCT00142805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tricaprilin
Description: Powder formulation will be mixed in a liquid (approximately 8 oz).
Study NCT00142805 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder formulation will be mixed in a liquid (approximately 8 oz).
Study NCT03932864 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MGTA-145
Description: MGTA-145 will be given in various doses intravenously
Study NCT02052284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sterile water application
Description: Nurses are trained in proper dispensing and application of water in a sterile gentle way that will minimize shear force on the skin, risk for skin injury, and the potential for spread of fecal flora.
Study NCT04167202 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydrogen-rich water
Description: Hydrogen-rich water (one hydrotherapy every 4 hours)
Study NCT03932864 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGTA-145
Description: MGTA-145 will be given in various doses intravenously
Study NCT03932864 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: plerixafor
Description: 240 µg/kg subcutaneously
Study NCT03932864 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: 240 µg/kg subcutaneously
Study NCT03932864 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given in various doses intravenously
Study NCT01121445 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: NeilMed nose and sinus irrigation
Description: Saline irrigation used daily plus CPAP with heated humidification for 4 weeks
Study NCT00907530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MULTIHANCE:
Description: MULTIHANCE ® 0.5 M,0.1 mmol/kg
Study NCT00907530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GADOVIST
Description: GADOVIST ® 1.0 M,0.1 mmol/kg
Study NCT03271372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV
Study NCT03271372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Collection
Description: Correlative studies
Study NCT03271372 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Peripheral Blood Collection
Description: Correlative studies
Study NCT03271372 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given IV
Study NCT04130724 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood ketone testing
Description: Ketone testing will be done using a blood beta-hydroxybutyrate (BHB) test at least five (5) times per day.
Study NCT04130724 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Breath ketone testing
Description: Ketone testing will be done using a breath acetone (BrAce) test at least five (5) times per day.
Study NCT02863172 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Consenting Proband Group: Participants fill out questionnaires about work, family history, medical history, and health habits at baseline. It should take about 20 minutes to complete the questionnaires. Participants also complete a health and lifestyle questionnaire, which contains 20 questions for men and 22 questions for women. Questionnaire should take about 10 minutes to complete. Follow-up questionnaire at least 1 time in 5 years to update medical, cancer, and family history.~Family Members (MDA Registered Patients) Group and Family Members (Not MDA Registered Patients) Group: Participants complete a health questionnaire, which collects information about their personal medical history, demographics (age, race, sex, and so on), and questions about their alcohol and tobacco use at baseline. Questionnaire should take about 20 minutes to complete. Participants complete follow-up questionnaire at least 1 time in 5 years to update their medical, cancer, and family history.
Study NCT02863172 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw/Saliva Sample
Description: About 2-3 tablespoons blood drawn. Participants may give a saliva sample instead.
Study NCT05009641 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-carnitine
Study NCT05009641 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine
Study NCT01341808 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epaxal Berna (virosomal hepatitis A vaccine)
Description: standard 0.5 mL dose of Epaxal Berna (virosomal hepatitis A vaccine) given at Day 0, Month 6.
Study NCT00541866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voreloxin injection and cytarabine
Description: Dose-escalation Phase~* Schedule A: vosaroxin injection (dose-escalation from 10 to 90 mg/m2) on Days 1 and 4 in combination with cytarabine (24-hour CIV infusion of 400 mg/m2/day × 5 days)~* Schedule B: vosaroxin injection (dose-escalation from 70 to 90 mg/m2) on Days 1 and 4 in combination with cytarabine (2-hour intravenous \[IV\] infusion of 1 g/m2/day × 5 days)~Expansion Phase The MTD determined in the dose-escalation phase was used in the expansion phase.~* Schedule A: 80 mg/m2 vosaroxin on Days 1 and 4 in combination with cytarabine (24-hour CIV infusion at 400 mg/m2/day × 5 days)~* Schedule B: 90 mg/m2 vosaroxin (dose-escalation) on Days 1 and 4 in combination with cytarabine (2 hour IV infusion at 1 g/m2/day × 5 days)
Study NCT02367001 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Normal invitation
Description: No modification and signed by the coordinating doctor as usual
Study NCT02367001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: revised invitation signed by the coordinating doctor
Description: Invitation with revised text and layout and signed by the coordinating doctor as usual
Study NCT02367001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Revised invitation signed by the attending physician
Description: signature typed or typed + handwritten
Study NCT01482169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FFR Measurement with IV Adenoscan® then with Regadenoson
Description: Testing will be completed during a Left Heart Catheterization (LHC). The first 48 eligible patients enrolled will receive an initial infusion of IV Adenoscan® through a peripheral vein at 140 mcg/kg/min. FFR measurements will be obtained utilizing a coronary pressure guide wire once peak hyperemia has been achieved. It takes about 84 seconds to reach peak hyperemia with Adenoscan®. Subsequently, these subjects will receive a dose of regadenoson at 0.4 mg through the same peripheral access site. FFR measurements will be obtained once peak hyperemia is achieved, which takes less than 30 seconds with regadenoson. Patients who react to either medication will be supported conservatively under close scrutiny.
Study NCT01482169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FFR Measurement with IV Adenoscan® then with Regadenoson
Description: Testing will be completed during a Left Heart Catheterization (LHC). The first 48 eligible patients enrolled will receive an initial infusion of IV Adenoscan® through a peripheral vein at 140 mcg/kg/min. FFR measurements will be obtained utilizing a coronary pressure guide wire once peak hyperemia has been achieved. It takes about 84 seconds to reach peak hyperemia with Adenoscan®. Subsequently, these subjects will receive a dose of regadenoson at 0.4 mg through the same peripheral access site. FFR measurements will be obtained once peak hyperemia is achieved, which takes less than 30 seconds with regadenoson. Patients who react to either medication will be supported conservatively under close scrutiny.
Study NCT01271075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilastine
Description: Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days
Study NCT02480166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8 weeks SOF/LED
Description: Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
Study NCT02480166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12 weeks SOF/LED
Description: Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are not treatment naïve or have cirrhosis will be assigned to 12 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
Study NCT01579565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS302
Description: OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced saline salt (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
Study NCT01579565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
Study NCT01359241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: closed-loop insulin delivery
Description: Insulin delivery via subcutaneous pump, adjusted according to computer-based algorithm advice, based on continuous glucose sensor readings
Study NCT01359241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual diabetes treatment regimen
Description: Usual non-insulin glucose lowering medications
Study NCT00096174 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab C225
Description: 400 mg/m\^2 IV over 120 minutes on Day 1, 250 mg/m\^2 IV over 60 minutes on Day 8, then weekly
Study NCT00096174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m\^2 IV over 30-60 minutes starting day 15 every 3 weeks \* 3 (Days 1, 22, and 43 of radiation therapy (RT))
Study NCT00096174 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: RT 70 Gy / 35 starting Day 15, 200cGy / d \* 7 weeks (35 fractions)
Study NCT00123279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microplasmin
Description: 25ug injected 1 hr prior to PPV, 24 hr and 7 days prior to PPV, 50ug injected 24 hr prior to PPV, 75ug injected 24 hr prior to PPV and 125ug injected 24 hr prior to PPV.
Study NCT03091998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CD-NP
Description: Participants will receive a subcutaneous injection of CD-NP (5 mcg / kg) daily for 3 days
Study NCT03091998 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive an \~ 1mL subcutaneous injection of normal saline, in lieu of Study Drug, for 3 days
Study NCT03233334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Purpose Project
Description: The purpose project intervention 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in life that helps them flourish.
Study NCT06600243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistance training + deep sea water
Description: A group that will perform a resistance training protocol with variable resistance and at the same time will receive a supplementation composed by deep sea water
Study NCT06600243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training + Placebo
Description: A group that will perform a resistance training protocol with variable resistance and at the same time will receive a placebo supplementation that have the same tasted than the deep sea water supplementation
Study NCT06600243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control + deep sea water
Description: A group that will maintain their usual live and at the same time will receive a supplementation composed by deep sea water
Study NCT06600243 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control + Placebo
Description: A group that will maintain their usual live and at the same time will receive a placebo supplementation that have the same tasted than the deep sea water supplementation
Study NCT06332768 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory support
Description: High-flow nasal oxygenation
Study NCT04167202 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RICE
Description: RICE protocol
Study NCT00846430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-Interferon alpha-2b
Description: age and weight dependant
Study NCT00846430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib (Celebrex)
Description: age and weight dependant
Study NCT00846430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (temodar)
Description: age and weight dependant
Study NCT00846430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate (Oncovin)
Description: age and weight dependant
Study NCT01827397 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EN41-UGR7C HIV vaccine
Study NCT01827397 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Study NCT02496273 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTL
Description: Mononuclear cells (Dendritic Cell,DC precursor) were isolated from the peripheral blood of gasric cancer by density gradient centrifugation and infected with rAAV/CEA virus.Maturation of the DC was induced by granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4) and tumor necrosis factor-alpha(TNF-alpha). On day 7, the DCs were collected and mixed with T cells at the ratio of 1 to 20 to induce cytotoxic T lymphocytes (CTL).The cells will be proliferated and infused by intravenous (IV) infusion into the patient.
Study NCT01036841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desmopressin tablet
Description: Administration of desmopressine tablet
Study NCT01036841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desmopressin MELT formulation
Description: Administration of desmopressine MELT formulation
Study NCT01828671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corn Tortilla
Description: Should the participant be eligible to participate, they will be scheduled for a study visit to assess the glycemic response of the corn tortillas.
Study NCT01828671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Soy Flour Corn Tortilla
Description: Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a low amount of soy flour.
Study NCT01828671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Soy Flour Corn Tortilla
Description: Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a moderate amount of soy flour.
Study NCT02248155 — intervention group
Intervention type: DRUG
Intervention: Pramipexole
Study NCT00737568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF
Description: Tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg tablet administered orally once daily